ICP-490 / InnoCare - LARVOL DELTA

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=68 | Not yet recruiting | Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

New P1/2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

ICP-490 is a highly potent and selective IKZF1/3 degrader with robust anti-tumor activities against multiple myeloma and non-Hodgkin’s lymphoma (AACR 2023) - "Background: Cereblon (CRBN)-targeting immunomodulatory drugs (IMiDs), i.e., thalidomide and lenalidomide, play pivotal roles in treating multiple myeloma (MM) patients...The immune modulation activity of ICP-490 has also been illustrated in a combinatory treatment with daratumumab, where low dose of ICP-490 leads to robust induction of IL-2 and granzyme B, and much improved efficacy of daratumumab in MM cell line NCI-H929... ICP-490 is a highly potent, orally bioavailable, next-generation CRBN-targeting IMiD with selective IKZF1/3 degradation. In various MM and NHL tumor models, it demonstrates superior tumor killing activities than currently approved IMiDs, including overcoming lenalidomide resistance. ICP-490 is now in phase I clinical trial."

Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CRBN • GSPT1 • GZMB • IFNG • IKZF1 • IKZF2 • IKZF3 • IL17RB • IL2 • SALL4 • TNFA

InnoCare Releases 2022 Annual Results and Business Highlights (Businesswire) - "ICP-490: Novel targeted protein degrader ICP-490 has entered clinical trial in China for the treatment of R/R multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL)."

New trial • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

InnoCare Announces First Subject Dosed in Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China (Businesswire) - "InnoCare Pharma...announced today that the first subject has been dosed in clinical trial of the Company’s novel targeted protein degrader ICP-490 in China."

Trial status • Hematological Malignancies • Multiple Myeloma • Oncology

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting (Businesswire) - "Data of InnoCare’s...robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting....Abstract Number: 3427:...Cell viability assays reveal robust in vitro efficacies of ICP-490 against various MM and NHL (including DLBCL) cell lines with nanomolar IC50. It also exhibits potent anti-proliferative activity in lenalidomide-resistant cell lines. In contrast to its tumor killing effect, ICP-490 shows no cytotoxicity against normal human cells. In vivo efficacy studies have further confirmed the effectiveness of ICP-490 against various MM and DLBCL xenografts."

Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=80 | Not yet recruiting | Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

InnoCare Announces Approval of Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China (Businesswire) - "InnoCare Pharma...announced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its novel targeted protein degrader ICP-490 for the treatment of multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL)."

New trial • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology